Trial Profile
A Multicenter, Four-Part, Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Adults With Moderate to Severe Pachyonychia Congenita
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Pachyonychia congenita
- Focus Registrational; Therapeutic Use
- Acronyms VALO
- Sponsors Palvella Therapeutics
- 23 Dec 2020 Primary endpoint of Patient Global Assessment of Activities difficulties (PGA-AD), which compared the last two weeks of the Phase 2 open-label treatment period to the last two weeks of the RI period (phase II portion) has been met, according to results presented in the Palvella Therapeutics media release.
- 23 Dec 2020 Primary endpoint of Patient Global Assessment of Activities Scale (phase III portion) has not been met, according to results presented in the Palvella Therapeutics media release.
- 23 Dec 2020 Results presented in the Palvella Therapeutics media release.